Funder
Janssen Pharmaceuticals Inc
MSD
ViiV Healthcare UK
Gilead Sciences Inc
Subject
Pharmacology (medical),Infectious Diseases,Microbiology (medical),General Medicine
Reference44 articles.
1. Biagio A Di, Cozzi-lepri A, Prinapori R, Angarano G, Gori A, Quirino T, et al. Discontinuation of initial antiretroviral therapy in clinical practice: moving toward individualized therapy 2016;71:263-71.
2. Evolution in real-world therapeutic strategies for hiv treatment: a retrospective study in southern Italy, 2014-2020;Papa;J Clin Med,2022
3. Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting;d'Arminio Monforte;J Antimicrob Chemother,2019
4. Durability of rilpivirine-based versus integrase inhibitor-based regimens in a large cohort of naïve HIV-infected patients starting antiretroviral therapy;Gagliardini;Int J Antimicrob Agents,2021
5. Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort;Mondi;J Int AIDS Soc,2019